Table 3 Univariate survival analysis (OS and DSS) considering ProMisE subgroups and L1CAM status within the p53 wt/NSMP subgroup
From: L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile
OS | DSS | |||||
|---|---|---|---|---|---|---|
# of events / n | Hazard ratio (95% CI) | LRT P value | # of events / n | Hazard ratio (95% CI) | LRT P value | |
ProMisE | 112 / 452 | 55 / 450 | ||||
p53 wt/NSMP L1CAM- (ref) | — | — | ||||
POLE | 0.81 (0.32–2.08) | <0.001 | 0.46 (0.06–3.58) | <0.001 | ||
MMR-D | 2.07 (1.27–3.37) | 2.99 (1.40–6.40) | ||||
p53 wt/NSMP L1CAM+ | 3.70 (1.77–7.76) | 6.94 (2.56–18.74) | ||||
p53 abn | 6.38 (3.90–10.42) | 11.52 (5.55–23.90) |
